A dendritic cell-targeting microparticle vaccine for treatment of Type 1 Diabetes

摘要

These preliminary studies demonstrate that our engineered microparticle vaccine formulations can: (a) modulate DC phenotype and further promote allogenic T cell hyporesponsiveness to exposed DCs; (b) prevent the onset of diabetes in NOD mice if treated at an age that is therapeutically relevant; (c) target DCs in vivo for uptake and trafficking. In the future, we will investigate diabetes prevention with the targeted MPs, as we expect improved uptake to further promote diabetes prevention.